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Shared care by paediatric oncologists and family doctors for 
long-term follow-up of adult childhood cancer survivors: 
a pilot study
Ria Blaauwbroek, Wemke Tuinier, Betty Meyboom-de Jong, Willem A Kamps, Aleida Postma
Summary
Background Since 75% of children with cancer will become long-term survivors, late eﬀ ects of treatment are an ever 
increasing issue for patients. Paediatric oncologists generally agree that cancer survivors should be followed up for 
the remainder of their lives, but they might not be the most suitable health-care providers to follow up survivors into 
late adulthood. We designed a 3-year study to assess whether shared-care by paediatric oncologists and family doctors 
in the long-term follow-up of survivors of childhood cancers is feasible, whether a shared-care model is compatible 
with collection of data needed for registration of late eﬀ ects, and how a shared-care model is assessed by survivors and 
family doctors.
Methods In 2004 and 2005, adult survivors of childhood cancers were randomly chosen from eligible patients diag-
nosed with childhood cancer (excluding CNS tumours) or Langerhans-cell histiocytosis between January, 1968, and 
December, 1997, and recalled to the long-term follow-up (LTFU) clinic at the University Medical Centre Groningen, 
Groningen, Netherlands, where they underwent physical and clinical assessments by an on-site family doctor (visit 1). 
At this visit, assessments were done according to guidelines of the UK Children’s Cancer Study Group Late Eﬀ ects 
Group, and late eﬀ ects were graded by use of Common Terminology Criteria for Adverse Events (version 3). Follow-up 
assessments were done 1 year later in 2005 and 2006 by local family doctors (visit 2), who were asked to return data to 
the LTFU clinic. At this visit, the local family doctors were asked to complete a three-item questionnaire and patients 
were asked to complete a seven-item questionnaire about their satisfaction with the shared-care model. At the next 
consultation, which was planned for the end of the study (visit 3), the on-site family doctor advised patients about 
future follow-up on the basis of their individual risk of late eﬀ ects. Main endpoints were numbers of participants, 
satisfaction ratings, and proportions of local family doctors who returned data that they obtained at visit 2 to the LTFU 
clinic. 
Findings 133 individuals were chosen at random from 210 enrolled adult survivors. 123 of 133 (92%) randomly selected 
survivors and 115 of 117 (98%) of their family doctors agreed to participate in the share-care programme. 103 of 
115 (90%) family doctors returned data to the LTFU clinic at visit 2. 89 of 101 (88%) of survivors were satisﬁ ed with 
this shared-care model, as were 94 of 115 (82%) family doctors; 18 of 115 (16%) family doctors had no views either way; 
and three of 115 (3%) family doctors were dissatisﬁ ed.
Interpretation Shared-care by paediatric oncologists and family doctors is feasible for long-term follow-up of adult 
survivors of childhood cancers. 
Introduction
Most children with cancer will become long-term 
survivors and many of them will be at risk of 
treatment-related adverse health outcomes. Estimations 
suggest that physical or psychosocial complications will 
develop in as many as two-thirds of these survivors. The 
severity of these complications vary from mild to severe, 
and might even be life-threatening.1,2 10% of survivors 
will die within 20 years of the end of treatment, some 
because of recurrence of primary disease, and others 
because of complications of previous treatment.3 To 
enable survivors to enjoy the best quantity and quality of 
life, identiﬁ cation and treatment of late eﬀ ects as early as 
possible is important.4 
For a long time, the discharging of paediatric patients 
with cancer after a disease-free interval of around 10 years 
was common practice. Nowadays, paediatric oncologists 
world-wide believe that a systematic plan for life-long 
screening and surveillance should be oﬀ ered to all 
survivors.5,6 Much eﬀ ort is being invested in the 
development of guidelines for assessment of late eﬀ ects of 
cancer treatment, such as the guidelines of the US 
Children’s Oncology Group, the UK Children’s Cancer 
and Leukaemia Group (CCLG), and the Scottish 
Intercollegiate Guidelines Network (SIGN). Up to now, 
many adult survivors are not being followed up on a 
regular basis.7 Of those who participate in follow-up 
programmes of childhood cancer, more than 90% are 
followed up by a paediatric oncologist in a paediatric 
institution.8 However, paediatric oncologists are not the 
most appropriate health-care workers to care for survivors 
into late adulthood. Patients who have been treated for 
cancer might have ongoing complex health needs and 
many comorbidities that need a range of approaches 
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provided through general practice. In the Netherlands, 
survivors usually have family doctors, most of whom are 
willing to participate in a shared-care programme.9 In a 
shared-care programme, family doctors participate in the 
screening of late eﬀ ects in adult survivors of childhood 
cancers in consultation with paediatric oncologists of the 
LTFU clinic.
Since the number of survivors of childhood cancers is 
expected to increase, identifying who should undertake 
long-term follow-up of such patients after achieving 
adulthood is important. Hospital-based life-long follow-up 
for all adult survivors will not only be very expensive, but 
also diﬃ  cult to organise because of the ever-increasing 
population. From an economic point of view, we have to 
look for alternative follow-up programmes with the lowest 
burden, not only for survivors, but also for the expanding 
health-care budgets in many western countries. Family 
doctors will treat increasingly more of these patients, with 
a mean of eight or nine patients who survived childhood 
cancers registered with every family doctor predicted by 
2010 (on the basis of a mean of 2350 patients registered 
for every family doctor).10 If guidelines and ongoing 
supervision were made available from clinics such as the 
long-term follow-up (LTFU) at the University Medical 
Centre Groningen (Groningen, Netherlands), the 
assessment of late eﬀ ects could be undertaken by family 
doctors. If serious late eﬀ ects, such as cardiac or endocrine 
complications were detected, survivors could be referred 
to an appropriate consultant. Involvement of family 
doctors in shared-care programmes for long-term 
follow-up would increase their knowledge about the 
unique needs of survivors of childhood cancers. 
To assess shared-care by family doctors and paediatric 
oncologists in long-term follow-up of survivors of 
childhood cancers, we designed a 3-year study to assess 
whether such a model is feasible, whether shared-care is 
compatible with collection of data needed for registration 
of late eﬀ ects, and how a shared-care model can be 
assessed by survivors and family doctors.
Methods
Patients
210 adult (ie, aged 18 years or over) survivors were 
enrolled into the study. Patients were randomly chosen 
by use of a computer program and recalled to the LTFU 
clinic in the ﬁ rst year of the study and were eligible if 
they had been treated at the paediatric oncology 
department of the University Medical Centre Groningen 
(Groningen, Netherlands) at least 5 years previously and 
were not involved in any childhood cancer follow-up 
programmes. Patients who were diagnosed with 
childhood cancer or systemic multifocal Langerhans-cell 
histiocytosis (LCH) between January, 1968, and December, 
1997, were included. Patients with tumours of the central 
nervous system were excluded because most of them 
were being followed up by a multidisciplinary 
neuro-oncology team.
Procedures
In 2004 and 2005, survivors were recalled to the LTFU 
clinic at the University Medical Centre Groningen 
(Groningen, Netherlands; visit 1). An on-site family 
doctor with a special interest in late eﬀ ects and who was 
employed by the LTFU clinic assessed the patients. 
Since Dutch guidelines were still under development at 
the time, the on-site family doctor used guidelines of 
the UK Children’s Cancer Study Group (UKCCSG) Late 
Eﬀ ects Group11 to assess the survivors. Previous 
diagnosis and treatment established patients’ risk-based 
assessments—eg, hormonal assessments, echocardio-
graphy, bone-mineral-density tests, or pulmonary-
function tests. Late eﬀ ects were graded by use of 
Common Terminology Criteria for Adverse Events 
(CTCAE; version 3).12 CTCAE grades adverse eﬀ ects 
from 0 to 4. Grade 1 eﬀ ects are small and usually 
asymptomatic. Grade 2 eﬀ ects are moderate, usually 
symptomatic, but do not impair daily activities. Grade 3 
eﬀ ects are severe and need more serious interventions. 
Grade 4 eﬀ ects are potentially life-threatening. 
Health-related quality of life (HRQoL) at visit 1 (and also 
later at visit 3) was assessed by the RAND 36-item health 
survey (RAND-36). RAND-36 is an internationally used 
validated, reliable, generic self-report questionnaire that 
has been translated into Dutch13 and validated for the 
Dutch population.14 RAND-36 contains eight subscales: 
physical functioning, social functioning, role limitations 
due to physical diﬃ  culties, role limitations due to 
emotional diﬃ  culties, mental health, vitality, bodily 
pain, and general-health perceptions. For each subscale, 
115 family doctors entered the study 121 survivors entered the study
117 family doctors of the 123 survivors 
        invited
      6 survivors dropped out
133 adult survivors were randomly 
         selected from 210 eligible survivors 
         and invited to participate
      10 survivors refused participation
      2 family doctors refused*
115 survivors were assessed by their 
        family doctor in second year
100 survivors received follow-up 
         advice at the LTFU clinic
   15 survivors received follow-up 
         advice by telephone
Figure: Trial proﬁ le
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scores were coded, summed, and transformed to a scale 
from 0 (worst health) to 100 (best health). The control 
group for the HRQoL analyses consisted of 
1036 people aged 18 years and over who took part in a 
previous health screening of the population of Emmen 
in The Netherlands.15 From the control group, mean 
scores of the subgroup aged 25–44 years (n=416) were 
used as reference values in our study. RAND-36 has 
been used in other studies to assess HRQoL in survivors 
of childhood cancers.16,17 
Follow-up of the assessed survivors was 1 year after 
their ﬁ rst visit, in 2005 or 2006 (visit 2), and was 
undertaken by local family doctors who had been sent 
information (from the on-site coordinating family doctor 
at the LTFU clinic) about patients’ histories, health risks, 
and necessary tests. Survivors were sent letters asking 
them to make appointments of at least half an hour with 
their family doctors. The letters were accompanied by 
forms that were to be completed by the family doctors 
during the physical assessments at visit 2 (there were two 
forms: one for medical history and one for physical 
assessment). To maintain a complete survivor database 
in our hospital, family doctors were asked to return these 
forms and the results of their tests. We assessed this 
shared-care model with a three-item questionnaire for 
family doctors that asked whether the information they 
had received from the LTFU clinic was suﬃ  cient to do 
the screening, whether they were satisﬁ ed with the 
collaboration, and whether they had any suggestions to 
improve the collaboration; survivors were also asked to 
complete a seven-item questionnaire about their views 
on their follow-up by use of a ﬁ ve-point Likert scale for 
their answers, ranging from very satisﬁ ed to very 
dissatisﬁ ed.
At the next consultation, which was planned 1 year after 
visit 2, in 2006 or 2007 (visit 3) and was done by the on-
site family doctor at the LTFU clinic, survivors were 
advised about future follow-up on the basis of their 
individual risk of late eﬀ ects. Survivors were divided into 
three groups as described by Wallace and colleagues.18 
First, those with very low risk of future eﬀ ects were to be 
followed up by a yearly health questionnaire by post that 
would be assessed by staﬀ  at the LTFU clinic. Second, 
survivors with moderate risk of late eﬀ ects (ie, those who 
received chemotherapy or low-dose radiation) were to be 
assessed yearly by local family doctors, and fast and direct 
methods of communication (ie, email or telephone) to 
one member of staﬀ  at the LTFU clinic were suggested. 
Third, survivors with high risk of severe late eﬀ ects—
including those who had received moderate-to-high doses 
of radiotherapy, underwent bone-marrow transplantation, 
or received mega therapy (ie, intensive high-dose 
treatment)—were to be followed up in a shared-care 
model as described earlier in this report. Many of these 
high-risk survivors would also need care by specialists, 
such as endocrinologists, cardiologists, and orthopaedic 
surgeons.
To justify the conclusion that this model is feasible for 
the long-term follow-up of adult survivors of childhood 
cancers, proportions of participants (ie, survivors and 
family doctors), satisfaction, and numbers of those who 
returned data should be high—as close to 100% as 
possible. The study did not need ethics or approval from 
an institutional review board or patients’ written 
consent.
Statistical analysis
Data were analysed by descriptive techniques that used 
frequencies, percentages, means, and medians as 
appropriate. One-sample t test was used to compare the 
mean RAND-36 scores of the study group with the mean 
scores of the Dutch norm (reference) group. 
Paired-sample test was used to compare the mean 
RAND-36 scores at the start (visit 1) and at the end 
(visit 3) of the study. Since the total study sample was 
small, diﬀ erences between cancer types were not 
analysed. A signiﬁ cance level of α=0·05 was applied in 
all analyses. Analyses were done with SPSS for Windows 
(version 14.0).
Participants (n=121) Non-participants (n=12)
Median age at study, years (range) 34 (19–60) 28 (19–49)
Median age at diagnosis, years (range) 6 (0–38) 4 (1–18)






Malignant lymphoma 20 1
Bone sarcoma 23 3
Soft-tissue sarcoma 6 1
Wilms’ tumour 4 0
Langerhans-cell histiocytosis 8 2
Other 7 2
Treatment (n)
Chemotherapy only 48 9
Radiotherapy only 5 0
Table 1: Demographic and clinical data of participating adult survivors and non-participants
Study group (n=121) Control group  (n=416) p
Physical functioning 84·9 (20·0) 89·7 (16·3) p=0·011
Social functioning 85·4 (18·9) 89·4 (17·0)  p=0·027
Role limitations due to physical problems 80·7 (31·8) 82·7 (32·2) p=0·0500
Role limitations due to emotional problems 86·6 (30·3) 84·6 (31·5) p=0·472
Mental health 77·6 (16·1)  77·9 (17·7) p=0·853
Vitality 62·9 (20·1) 68·2 (18·9) p=0·005
Bodily pain 83·5 (19·2)  84·0 (22·9) p=0·787
General health perceptions 67·4 (21·7) 75·9 (20·2) p<0·0001
Table 2: Means and SDs for RAND-36 subscales, in survivors and in Dutch controls (aged 25–44 years) at 
visit 1 
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Role of the funding source
The sponsor of the study had no role in the study design, 
data collection, data analysis, interpretation, or writing of 
the report. WT had access to the raw data. RB had full 
access to all the data and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
Of 210 enrolled adult survivors, 133 individuals were 
chosen at random and recalled by letter to the LTFU 
clinic in the ﬁ rst year of the study (visit 1; ﬁ gure). The 
participants included eight bone-tumour survivors 
(osteosarcoma or Ewing sarcoma) who were older than 
18 years at diagnosis and who had been treated when 
chemotherapy for osteogenic sarcoma was given by 
paediatric oncologists. Ten out of the 133 (8%) invited 
survivors refused for the following reasons: one patient 
was severely mentally retarded; two patients had an 
anxiety disorder and were afraid to return to the hospital; 
and the other seven patients felt well but did not wish to 
look back at their cancer experience. Therefore, 123 (92%) 
survivors agreed to take part in this study. Six of these 
survivors agreed to participate in follow-up, but were not 
prepared to attend the clinic visits and requested that all 
assessments were done by local family doctors. Although 
these six individuals had all three visits at their local 
practice, they were included in this study. 115 of 117 (98%) 
of the approached local family doctors (some had more 
than one patient) were willing to collaborate in the 
shared-care model, and two (2%) doctors refused (the 
two patients of these two doctors were invited separately 
by the LTFU clinic, but did not enter this study). In total, 
12 of 133 invited survivors did not participate in the study, 
therefore, 121 survivors entered this study. Table 1 shows 
characteristics of all 133 individuals. Survivors completed 
HRQoL assessments by use of RAND-36 subscales. 
Table 2 shows the outcomes of the RAND-36 subscales 
for the study group, and the mean scores from the 
available Dutch reference group. Survivors showed 
signiﬁ cantly lower HRQoL scores compared with the 
control group on the subscales for physical functioning 
(p=0·011), social functioning (p=0·027), vitality (p=0·005), 
and general-health perceptions (p<0·0001). 
At visit 2, 115 of 121 (95%) survivors were assessed by 
local family doctors. Of the six survivors who were not 
assessed, two survivors had left the country, two survivors 
were starting treatment with growth-hormones and 
therefore did not have time to visit their local family 
doctor, and two survivors decided to end follow-up 
because they did not want to be reminded of their cancer 
(ﬁ gure). Completed forms for medical history and 
physical assessment were returned by 103 of 115 (90%) 
local family doctors, and two (2%) local family doctors 
reported ﬁ ndings of their assessments by telephone 
because their patients had forgotten to take the forms 
with them to visit 2. Complete data, including those for 
laboratory tests, radiographs, and echocardiograms were 
received by the LTFU clinic from 98 of 115 (85%) local 
family doctors. 
The seven-item satisfaction questionnaire was 
completed by 101 of 115 (88%) survivors (table 3). 89 of 
these 101 (88%) survivors were satisﬁ ed with the care 
given by the local family doctors at visit 2. 14 of the 
101 (14%) survivors thought that their local family doctor’s 
knowledge of their medical history was inadequate. The 
most frequent remarks for these patients were: “I had the 
feeling that the family doctor did not know what he/she 
was expected to do” (seven of 101 [7%] survivors), “there 
was too little time to perform the investigations” (ﬁ ve of 
101 [5%] survivors), and, “I had the feeling the family 
doctor was reluctant to perform the investigation” (three 
of 101 [3%] survivors).
Data from the three-item questionnaire for local family 
doctors showed that 94 of the 115 (82%) participating 
local family doctors were satisﬁ ed with this shared-care 
collaboration and thought the information they had 
received from the LTFU clinic was adequate, 18 of 
115 (16%) local family doctors had no opinion, and three 
of 115 (3%) local family doctors were dissatisﬁ ed.
Patients, n (%)
Satisﬁ ed with care given by doctor 
Very satisﬁ ed or satisﬁ ed 89 (88)
Neutral 6 (6)
Not satisﬁ ed 5 (5)
Satisﬁ ed with time available during screening by doctor
Very satisﬁ ed or satisﬁ ed 88 (87)
Neutral 3 (3)
Not satisﬁ ed 8 (8)
Satisﬁ ed with doctor’s knowledge of my medical history
Very satisﬁ ed or satisﬁ ed 78 (77)
Neutral 8 (8)
Not satisﬁ ed 14 (14)
Doctor’s attitude was friendly 
Very friendly or friendly 94 (93) 
Neutral 2 (2)
Not friendly 3 (3)
Satisﬁ ed with answers given by doctor
Very satisﬁ ed or satisﬁ ed 85 (84) 
Neutral 7 (7)
Not satisﬁ ed 8 (8)
Satisﬁ ed with booklet, summary of diagnosis, and treatment I received (n=121*)
Very satisﬁ ed or satisﬁ ed 106 (88)
Neutral 13 (11)
Not satisﬁ ed 2 (2)
Before being recalled to follow-up, I was already informed about possible late toxic eﬀ ects (n=121*)
Yes 36 (30)
No 85 (70)
Data are for 101 of 115 (88%) patients who completed satisfaction questionnaires. *All 121 patients who entered the 
study were able to answer this question. Percentages might not add to 100% due to rounding. 
Table 3:  Patient satisfaction with shared-care follow-up according to Likert scale
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Before visit 1, 85 of the 121 (70%) survivors had not 
received information about the possibility of late eﬀ ects. 
At visit 1, 64 of 121 (53%) survivors had mild late eﬀ ects 
(grade 1 or 2) and 48 of 121 (40%) survivors had 
moderate-to-severe late eﬀ ects (grade 3 or 4); additionally 
85 of 121 (70%) survivors had two or more late eﬀ ects 
and 37 of 121 (31%) survivors were diagnosed with 
previously unknown grade 2–4 late eﬀ ects  that needed 
treatment or closer monitoring. The most commonly 
recorded late eﬀ ects were cosmetic, eg, amputations, 
scars from surgery, asymmetric body growth due to 
radiation damage (35 of 121 [29%]), orthopaedic (24 of 
121 [20%]), endocrine deﬁ ciencies (20 of 121 [17%]), 
infertility (19 of 121 [16%]), cardiac damage (11 of 
121 [9%]), and second malignant tumour (11 of 121 [9%]). 
Five survivors had a second malignant tumour (one 
meningioma, one oesophageal carcinoma, and three 
basocellular carcin omas) that had not been diagnosed 
before.
At visit 3, 100 patients received advice at the LTFU clinic 
and 15 patients received advice by telephone. RAND-36 
was completed by 110 of 115 (96%) survivors (data not 
shown). No signiﬁ cant diﬀ erences in any of the subscales 
were noted between visit 1 and visit 3. More detailed 
information about late eﬀ ects and HRQoL of almost the 
same study group has been published in an earlier study 
in which 117 of 121 (97%) survivors of our current study.19 
Discussion
123 of 133 (92%) invited survivors and 115 of 117 (98%) 
family doctors agreed to take part in the shared-care 
programme. Since 89 of 101 (88%) survivors who 
completed satisfaction questionnaires and 94 of 115 (82%) 
family doctors were satisﬁ ed with the programme, our 
ﬁ ndings have shown that shared-care by paediatric 
oncologists and family doctors is feasible for long-term 
follow-up of adult survivors of childhood cancers.
Collection of long-term follow-up data for registration 
purposes of late eﬀ ects is acceptable. However, 
improvement of the exchange of information between 
family doctors and the LTFU clinic remains a challenge. 
Shared electronic health records, including information 
about diagnosis, treatment, and future screening practices, 
might be helpful.20 In our earlier study,9 110 of 233 (47%) 
family doctors preferred communication by email or by 
use of a website to submit forms. In the same study, most 
family doctors were willing to participate in long-term 
follow-up of adult survivors of childhood cancers, on the 
condition that guidelines and adequate medical information 
were provided and that there was one contact person at the 
LTFU clinic. The family doctors in that study were a 
diﬀ erent group to that in the present study; although, there 
was an overlap of 13 family doctors between both studies. 
Models of shared care have been developed for chronic 
diseases such as diabetes, hypertension, and asthma,21,22 
and there are some examples of shared oncological care for 
adult patients with cancer.23,24 Some studies suggest that 
family doctors are willing to take part in follow-up care of 
patients with cancer,9,25 and that hospital follow-up provides 
no advantages compared with long-term follow-up in 
primary-care settings.22,24 “Developing personal relation-
ships”, “gaining mutual respect”, and “increasing medical 
knowledge for the beneﬁ t of their patients”, seemed to be 
the most important motivational factors to persuade family 
doctors to collaborate with specialist services.26 For 
shared-care models to be successful, family doctors need 
to view such programmes as an improvement from usual 
care in general practice, rather than as a downgrade from 
hospital practice.27
In our current study, most (85 of 121 [70%]) of the 
survivors who were recalled had not received information 
about the possibility of late eﬀ ects from treatment before 
their visit, and consequently, were at risk of delayed 
medical care if health problems were to occur. Therefore, 
survivors should be fully informed and family doctors 
should know about the possible late eﬀ ects of cancer 
treatment and their eﬀ ects on health; participation in a 
shared-care programme should help update family 
doctors’ knowledge. In our study, all family doctors were 
given information on their patients’ history, health risks, 
and required tests. But 14 of 101 (14%) survivors were 
dissatisﬁ ed with their family doctors’ knowledge about 
their medical history. Improvement of family doctors’ 
knowledge about late eﬀ ects is important because this is 
important for survivors of childhood cancers.28 Training 
in survivorship care should be incorporated into training 
programmes for family doctors.
At present, not all long-term survivors are in long-term 
follow-up, and as age increases, the likelihood of receiving 
adequate long-term follow-up decreases.7 Furthermore, 
whereas the incidence of many modiﬁ able late eﬀ ects 
of treatment increases with age, the likelihood of 
receiving cancer-related care decreases with time. Many 
cancer survivors are discharged years before follow-up, 
and some services still discharge survivors as soon as 
they reach adulthood. 
Survivors sometimes view hospital-based follow-up as 
problematic as they reach adulthood. Loss of long-term 
cancer survivors to follow-up should be avoided because 
many of the potentially serious late eﬀ ects might not 
manifest until decades after completion of treatment. 
Oeﬃ  nger and co-workers29 reported that patients 
diagnosed with malignancy between 1970 and 1986 and 
who had subsequently survived cancer, showed increased 
vulnerability to diseases associated with ageing, such as 
second cancers, cardiovascular disease, renal disease, 
musculoskeletal disorders, osteoporosis, and infertility, 
compared with their siblings.29 Therefore, adult survivors 
of childhood cancers should be recalled for follow-up. 
In our study, a substantial proportion (48 of 121 [40%]) 
of adult survivors had moderate-to-severe late eﬀ ects. In 
another study,19 such survivors had signiﬁ cantly lower 
quality of life compared with survivors who had no or 
only mild late eﬀ ects. In the current study, 
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37 of 121 (31%) survivors had previously undetected late 
eﬀ ects that needed treatment or closer monitoring. 
Therefore, the recall of these survivors was worthwhile 
for managing the late eﬀ ects and for minimising 
morbidity and the risk of severe complications. The 
long-term costs of early identiﬁ cation and treatment of 
late eﬀ ects need further study. Although we did not 
undertake a cost analysis, shared care probably costs less 
than follow-up in an LTFU clinic alone. As the number of 
cancer survivors is increasing, the time has come to 
identify new models of cost-eﬀ ective long-term 
follow-up.
Up to now, long-term follow-up of childhood-cancer 
survivors has been mainly organised by paediatric 
oncologists, and family doctors have rarely been 
involved. Yet, paediatric oncologists are ill-equipped to 
assess adult patients. Highlighting the need for new 
approaches to long-term care, Goldsby and colleagues30 
suggested four possible models—those driven by 
patients, family doctors, paediatric oncologists, or adult 
medicine health-care workers. Each model has its 
advantages and disadvantages, and more than one 
model might be needed.31 Since childhood-cancer 
survivors are a very heterogeneous group, Wallace and 
co-workers18 suggested that follow-up should be 
organised into three levels according to a patient’s 
individual risk proﬁ le. 
Clear advantages of follow-up care given by local family 
doctors rather than by hospital staﬀ  include less patient 
travel, shorter waiting times, better patient familiarity 
with surroundings (ie, the doctor’s practice), and less 
stigmatisation. As survivors grow older and possibly 
develop additional chronic illnesses of age, access to care 
in the context of total health needs is more useful. 
In the past 10 years, studies have begun to document 
late eﬀ ects of treatment in survivors of adult cancers.32–34 
Care for these survivors, provided by oncologists, generally 
does not extend beyond surveillance for recurrence of the 
cancer, and after about 5–10 years, patients are discharged 
without speciﬁ c plans for monitoring.
Busy oncology practices, which focus on patients 
undergoing active treatment, are not appropriate for 
life-long follow-up of cancer survivors. Collaboration 
with family doctors in a shared-care model might provide 
a solution. A few studies23,24 have suggested that such a 
model is applicable to the care of adult cancer survivors. 
Given predictions that 300 million people will be 
diagnosed with cancer over the next 15 years, and over 
one-third of these will become cancer survivors,35 
collaborative shared care between specialists and family 
doctors is needed.
Our study has some limitations. We did not use 
predeﬁ ned criteria to establish whether our model would 
be successful enough to progress to the next phase of a 
large study. However, we think there is no standard of 
what would be an acceptable amount of participation, 
satisfaction, or return of requested data.  
Since we only recalled survivors who were not receiving 
any kind of follow-up, we could not compare our model to 
others. More studies are needed to assess whether a 
shared-care approach results in an equitable standard of 
care for survivors. Family doctors already have the skills 
to screen patients at increased risk of developing health 
problems such as diabetes and cardiovascular disease. 
With easy ways to communicate with LTFU clinics and 
the availability of guidelines, they should also be able to 
screen adult survivors of childhood cancer. We wish to 
emphasise that the success of a shared-care model 
depends on a key coordinator, who could be an academic 
family doctor with an interest in late eﬀ ects (as used in 
this study), a nurse practitioner, or a dedicated nurse. 
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